COO
Catalysts
Key Risks
The Opportunity
Cooper Companies makes contact lenses and fertility equipment - two very different businesses stapled together under one corporate roof. Their contact lens business (CooperVision) is excellent: they're one of four companies that collectively control nearly 90% of the market, and they hold the only FDA-approved contact lens designed to slow nearsightedness in children. Their fertility business (CooperSurgical) covers everything from IVF equipment to the only hormone-free IUD in the U.S. Together they pull in over $4 billion a year in revenue.
The stock has been punished this year, down about 12% in 2026, for two main reasons. First, the company had to pay out over $270 million to settle lawsuits related to a recalled batch of embryo culture media used in fertility treatments - that wiped out an entire quarter's earnings on paper. Second, their business in Japan and China has slowed down meaningfully, and management admitted the weakness could last into 2027.
But here's what makes this interesting: an activist investor named Jana Partners has built a $255 million stake and is pushing the company to split apart or sell the fertility division. That process is already underway - the company confirmed it's in active discussions with multiple potential buyers. If CooperSurgical gets sold at a reasonable price, the remaining contact lens business would likely be valued more highly by the market as a focused, pure-play company in a growing industry with limited competition.
The main risk is that the sale doesn't happen, or happens at a disappointing price. The Asia slowdown could also drag on longer than expected, and there's an ongoing class action lawsuit over genetic testing practices that could generate additional costs. At today's price of roughly $72, the stock appears to be approximately fairly valued - not a screaming bargain, but not overpriced either. The real upside depends on whether the strategic review delivers a value-unlocking transaction. Without that catalyst, you're paying a reasonable price for a good business growing at mid-to-high single digits.
How we got to $58 - $76
Breakdown
Cooper's balance sheet shows $12.48B in total assets against $4.24B in total liabilities as of Q2 2026, yielding $8.24B in book equity ($42.27/share). However, the composition demands scrutiny. A significant portion of assets is intangible - the company has accumulated goodwill and intangible assets through serial acquisitions including Cook Medical (Nov 2023), a fertility company (Jun 2024), and a U.S.-based medical device company (Aug 2024), all visible in the 10-K XBRL data.
These intangibles (customer relationships, technology-based assets, trademarks) are carried at amortized cost and represent a substantial share of the $12.48B asset base. Given that CooperSurgical is actively being shopped to buyers [CooperCompanies Q2 2026 Earnings Call Highlights, Yahoo Finance, June 2026], the fair value of these intangibles depends heavily on transaction outcomes - they could realize above or below book. On the liability side, total debt stands at $2.46B ($598.9M current + $1.86B long-term), with debt/equity at a manageable 0.30.
Critically, Q2 2026 saw a $324.1M litigation accrual for embryo culture media settlements, offset by $52.5M in insurance recoveries [CooperCompanies Q2 2026 8-K Filing, StockTitan, June 2026]. With 95%+ of claimants resolved, the remaining litigation liability tail is diminishing but the PGT-A class action introduces residual uncertainty [Cooper PGT-A Embryo Genetic Testing Class Action, Berger Montague]. Cash of $138.8M is thin relative to the company's scale, leaving limited buffer.
Net-net, the balance sheet is acceptable but asset-heavy with acquisition-driven intangibles whose realizable value is uncertain until the CooperSurgical sale process concludes.
Cooper generates solid free cash flow of $569.5M (TTM), representing a FCF yield of approximately 4.0% on the current market cap. Management raised FY2026 FCF guidance to approximately $650M excluding litigation payouts, with a $2.2B cumulative FCF target for 2026-2028 reaffirmed [Cooper Companies Q2 2026 Earnings Call Highlights, Yahoo Finance, June 2026]. Capital allocation has been tilted heavily toward acquisitions - the company completed at least three deals between late 2023 and mid-2024 (Cook Medical, a fertility company, and a medical device company).
The company pays no dividend (yield 0%, payout ratio 0%), which is notable for a mature healthcare business generating $570M+ in annual FCF. There are no material share buybacks evident in the data - shares outstanding remain at 194.9M. Debt has been reduced modestly from $2.58B (Q4 2024) to $2.46B (Q2 2026), suggesting some cash flow is directed toward deleveraging.
The activist criticism from Browning West, which slammed Cooper's 'growth at all costs' approach [Activist Investor Drops Scathing Letter, Nov 2025], and Jana Partners' push for a breakup [CNBC, October 2025], both center on capital allocation - specifically that acquisitive growth in CooperSurgical has not created commensurate shareholder value. The FCF-to-revenue conversion of approximately 14% is healthy, and the $2.92/share in FCF provides reasonable coverage for debt service. However, the lack of capital return to shareholders despite strong cash generation is a legitimate governance concern.
Cooper has delivered consistent revenue growth from $1.97B (2016) to $4.09B (2025), representing a roughly 8.5% CAGR over nine years. Revenue growth has been steady: 7.9% in FY2025, following $3.90B in FY2024 and $3.59B in FY2023. Gross margins have improved materially, from 59.4% (2016) to 65.5% (FY2025), reflecting favorable product mix shift toward premium daily disposable lenses (MyDay, Clariti).
However, operating margins tell a more nuanced story - FY2025 operating margin of 16.7% ($682.9M/$4.09B) was slightly below FY2024's 18.1% ($705.7M/$3.90B), and well below FY2019's 20.6% ($546.7M/$2.65B on a smaller base). GAAP net income has been volatile: $466.7M (2019), $238.4M (2020), $2.94B (2021 - clearly includes a large one-time gain), $385.8M (2022), $294.2M (2023), $392.3M (2024), $374.9M (2025). Earnings consistency has been beaten each of the last 8 quarters on a non-GAAP basis, which is encouraging.
The Q2 2026 GAAP loss of $77.9M ($-0.40 EPS) is entirely attributable to the $271.6M net litigation charge; non-GAAP EPS of $1.21 beat estimates of $1.10 and represented 26% YoY growth [CooperCompanies Q2 2026 Earnings Call Highlights, Yahoo Finance, June 2026]. On balance, the top-line track record is strong and consistent, but GAAP earnings volatility from acquisitions, restructurings, and now litigation creates noise that makes trend analysis difficult.
Analysts project 9.8% EPS growth over the next 5 years, which aligns reasonably with the company's historical revenue CAGR of ~8.5% plus modest margin expansion potential. The forward P/E of 14.1 at $72.32 implies forward EPS of approximately $5.13, consistent with the non-GAAP run rate (Q1 $1.10 + Q2 $1.21 = $2.31 for H1, suggesting $4.80-5.20 for the full year). Management guided FY2026 revenue to $4.28-4.32B (5-6% growth, 3.5-4.5% organic), but cut guidance due to Asia-Pacific consumer weakness in Japan and China expected to persist through Q3 and potentially into 2027 [Cooper Companies forecasts $4.28B-$4.32B fiscal 2026 revenue, Seeking Alpha, June 2026].
Growth drivers include: (1) the ongoing trade-up cycle from hydrogel to silicone hydrogel daily disposables, (2) myopia management via MiSight - the only FDA-approved soft contact lens for myopia control in children [CooperVision MiSight, CooperVision], and (3) the global contact lens market growing at 4.4-7.1% CAGR through mid-2030s [Contact Lenses Market Size, Fortune Business Insights]. Key assumption: if CooperSurgical is divested, the remaining CooperVision business would likely command a higher multiple as a pure-play in a growing oligopoly. The reverse DCF implies a 10.4% growth rate, modestly above the analyst consensus of 9.8%, suggesting the stock is pricing in slightly optimistic growth assumptions.
The PEG ratio of 1.43 indicates reasonable but not cheap growth-adjusted valuation.
Cooper operates in a tight oligopoly where the top four contact lens makers (J&J ~37%, CooperVision ~26%, Alcon ~26%, Bausch+Lomb ~10%) control approximately 88.7% of the North American market [USA Contact Lenses Market, Ken Research]. This market structure creates meaningful barriers to entry: manufacturing scale, regulatory approvals, optical professional relationships, and brand trust all compound over time. CooperVision holds a unique regulatory moat with MiSight 1 day, the only FDA-approved soft contact lens for myopia control in children - a product addressing the WHO-projected 3.36 billion myopia cases by 2030 [Contact Lenses for Myopia Control Market, DataIntelo].
The company's switching costs are moderate - eye care professionals develop familiarity with fitting protocols and patients develop brand loyalty, but switching is not as sticky as in enterprise software. CooperSurgical's moat is narrower - Paragard holds 17% of the US IUD market as the only hormone-free option, but faces intense litigation risk and competitive pressure. The fertility business benefits from Cooper's broadest medical device coverage of the entire IVF cycle, but this franchise is being actively shopped to buyers.
Overall, CooperVision's moat within the contact lens oligopoly is durable, but the combined entity's moat is diluted by CooperSurgical's weaker competitive position.
CEO Al White has led since May 2018, having previously served as CFO, providing institutional continuity. The management team has delivered consistent revenue growth and has beaten non-GAAP EPS estimates for at least 8 consecutive quarters. However, the capital allocation track record is mixed.
The acquisitive strategy - particularly the Cook Medical acquisition and fertility company purchases - drew sharp criticism from activist investors. Browning West published a scathing letter criticizing 'growth at all costs' [Activist Investor Drops Scathing Letter, November 2025], and Jana Partners built a $254.9M position (15.3% of Jana's portfolio) pushing for a breakup [JANA Partners Stock Position, The Stock Observer, August 2026]. The board has been responsive: appointing new Chair Colleen Jay (former P&G executive) in January 2026, adding STERIS CEO Emeritus Walter Rosebrough in January 2026, and Envista CEO Paul Keel in July 2026 [CooperCompanies Board Appointments, CooperCompanies IR].
Insider ownership at 0.67% is low, suggesting limited skin-in-the-game alignment. The formal strategic review launched in December 2025 [GlobeNewsWire, December 4, 2025] and active CooperSurgical sale discussions represent a positive governance response, though it took activist pressure to catalyze the review. Management cannot be fully assessed through data alone - I cannot evaluate interpersonal dynamics, board deliberation quality, or strategic conviction beyond what the track record shows.
Three material risk vectors stand out. First, litigation: the embryo culture media recall generated a $324.1M gross charge in Q2 2026 with 95%+ of 1,500+ claimants settled, but the PGT-A genetic testing class action filed by Berger Montague represents an open-ended liability with unknown magnitude [Cooper PGT-A Class Action, Berger Montague]. Second, geographic concentration risk: management flagged Japan and China consumer weakness that forced a guidance cut, with softness expected to persist potentially into 2027 [Seeking Alpha, June 2026].
Asia-Pacific is the fastest-growing region for contact lenses, so prolonged weakness there directly impacts the highest-growth opportunity. Third, execution risk around the strategic review: the CooperSurgical sale process is active but no deal has been announced as of August 2026. A failed or underpriced transaction would disappoint shareholders who have priced in breakup value.
Additional risks include: FX exposure (the company operates globally with significant non-USD revenue), potential disruption from smart/tech-enabled contact lenses in the long term [Contact Lenses Are Evolving, Vocal Media], and key customer concentration in the eye care professional channel. The 3.83% short float and 2.54 days-to-cover suggest moderate but not extreme bearish positioning.
The contact lens market is structurally attractive: growing at 4.4-7.1% CAGR, driven by rising myopia prevalence globally, and operating as a stable oligopoly with high barriers to entry [Contact Lenses Market Size, Fortune Business Insights]. Cooper's #2-3 position (depending on geography) is defensible, and the trade-up cycle from monthly to daily disposables provides a durable multi-year tailwind. The fertility/ART market is even more attractive structurally, projected to grow from $30.1B (2024) to $60.7B (2033) at 8.1% CAGR [Assisted Reproductive Technology Market Report 2026, Astute Analytica].
Institutional sentiment is net positive: 1,444 institutions hold COO shares with net inflows of $2.72B vs outflows of $2.15B over 12 months, indicating accumulation. Analyst consensus at 2.05 (buy-leaning) with an $80.38 target (+11% upside) reflects moderate optimism. The Jana Partners activist presence ($254.9M stake) acts as a catalyst forcing value-surfacing actions.
The key sentiment question is whether CooperSurgical's divestiture will unlock the sum-of-parts discount that activists have identified - the market appears to be partially pricing this in but awaiting confirmation.